Asheville Gastroenterology Associates is currently engaged in the following clinical trials. If you or someone you know, is over 18 years of age and are interested in any of our current clinical trials listed, you may contact us for more information to see if you qualify. If eligible, most trials will cover the cost of trial-related expenses and/or stipend. Email research@ashevillegastro.com your contact information and a study coordinator will contact you.
Liver Studies:
1) EXACT 2021-01- ALTUS: PERFORMANCE OF A MULTI-TARGET HEPATOCELLULAR CARCINOMA (HCC) TEST IN SUBJECTS WITH INCREASED RISK – PI-HARLAN – ANN JONES #3209
Ulcerative Colitis studies:
1) EXIGEM – VEDO-4054: AN OPEN-LABEL, PHASE 4, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE INDUCTION OF RESPONSE AND REMISSION OF VEDOLIZUMAB DUAL TARGETED THERAPY WITH TOFACITININB IN ADULT PATEINTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS – PI: HARLAN – CONTACT: GRACE GRIFFIN X3208 ** STANDARD Q8WK VEDOLIZUMAB INFUSIONS WITH 8 WEEKS OF TOFACITINIB DURING INDUCTION**
Crohn’s Disease Studies:
1) ASTRAZENECA- A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD7798 IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (AMALTHEA)- PI: HARLAN - CONTACT SUSAN WESTCOTT X3205 - **BIOLOGIC NAIVE OR EXPERIENCED** NOVEL BIOLOGIC REDUCING T CELL ACTIVITY IN GUT MUCOSA** INCLUDES OPEN-LABEL CROSSOVER AND EXTENSION**
2) ABBVIE- A PHASE 2A MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE- PI: HARLAN- CONTACT SUSAN WESTCOTT x3205- **BIOLOGIC EXPERIENCED ONLY** NO PLACEBO ARMS** 2 NOVEL BIOLOGICS +/- SKYRIZI** LONG TERM EXTENSION W/ SKYRIZI**
Opening Soon:
Ulcerative Colitis studies
AMETRINE-1 – GA45329: A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS – PI: HARLAN – CONTACT: ANN JONES X3209 **BIOLOGIC NAIVE OR EXPERIENCED** TL1A ANTAGONIST** INCLUDES OPEN-LABEL CROSSOVER AND EXTENSION**
MASH Cirrhosis Studies:
BIO89-100-132: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) – PI: HARLAN – CONTACT: ANN JONES X3209 **FIBROBLAST GROWTH FACTOR ANALOG **WEEKLY SUBQ INJECTION